Value in Health

Are Australians Able to Access New Medicines on the Pharmaceutical Benefits Scheme in a More or Less Timely Manner? An Analysis of Pharmaceutical Benefits Advisory Committee Recommendations, 1999-2003
pp. 205-212(8)
Authors: Wonder, Michael J.; Neville, A. Munro; Parsons, Richard

Trends in the Measurement of Health Utilities in Published Cost-Utility Analyses
pp. 213-218(6)
Authors: Brauer, Carmen A.; Rosen, Allison B.; Greenberg, Dan; Neumann, Peter J.

An Economic Evaluation of Two Ototopical Treatments for Acute Otitis Media in Tympanostomy Tube Patients
pp. 219-226(8)
Authors: Roland, Peter S.; Waycaster, Curtis R.; Wall, G. Michael; Glass, Jeffrey D.

Estimating the Cost-Effectiveness of Fluticasone Propionate for Treating Chronic Obstructive Pulmonary Disease in the Presence of Missing Data
pp. 227-235(9)
Authors: Briggs, Andrew H.; Lozano-Ortega, Greta; Spencer, Sally; Bale, Geraldine; Spencer, Michael D.; Burge, P. Sherwood

Managing Meningococcal Disease in the United States: Hospital Case Characteristics and Costs by Age
pp. 236-243(8)
Authors: O'Brien, Judith A.; Caro, J. Jaime; Getsios, Denis

Probabilistic Analysis and Computationally Expensive Models: Necessary and Required?
pp. 244-252(9)
Authors: Griffin, Susan; Claxton, Karl; Hawkins, Neil; Sculpher, Mark

Indirect Costs and Cost-Effectiveness Analysis
pp. 253-261(9)
Author: Ernst, Richard

Comparing the EQ-5D and the SF-6D Descriptive Systems to Assess Their Ceiling Effects in the US General Population
pp. 262-271(10)
Authors: Bharmal, Murtuza; Thomas, Joseph

Fraction of Nursing Home Admissions Attributable to Urinary Incontinence
pp. 272-274(3)
Authors: Morrison, Alan; Levy, Richard

Applying the Grid Computation in Long-Term Retrospective Health Insurance Data Analysis
pp. 275-275(1)

Is Rosuvastatin Really a More Efficient Therapeutic Option than Atorvastatin?
pp. 276-277(2)

Formulary Decision-Making Should Rely on the Best Available Evidence
pp. 277-279(3)